{"entity":{"id":"nct07609823","kind":"trial","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","aka":[],"tldr":"A phase 2 trial of Lacutoclax in chronic lymphocytic leukaemia, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.","summary":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL is a phase 2 interventional study registered as NCT07609823 by Guangzhou Lupeng Pharmaceutical Company LTD., with 75 participants planned, started 2026-07-14 and due to reach its primary completion in 2028-03-30. Interventions recorded: Lacutoclax.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07609823","url":"https://clinicaltrials.gov/study/NCT07609823"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll","cll-relapsed"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lupeng-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07609823","phase":"2","setting":"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Lacutoclax (LP-108) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","started":"2026-07-14","startedType":"actual","enrolled":75,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07609823/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/"}],"company":[{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","route":"/companies/lupeng-pharmaceuticals/"}]}}